ViewRay (OTCPK:VRAY.Q) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

VRAY.Q 주식 개요

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally.

회사 소개

VRAY.Q 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

보상

위험 분석

지난 5년간 매년 수익이 6.6% 씩 감소했습니다.

의미 있는 시가총액이 없습니다. ( $18K )

최근 3개월간 주가 변동폭 심해

cash runway 경력이 1년 미만입니다.

ViewRay, Inc. 경쟁사

Nanomix

OTCPK:NNMX

US$4.9k

American Bio Medica

OTCPK:ABMC

US$4.8k

Lucira Health

OTCPK:LHDX.Q

US$4.2k

Motus GI Holdings

OTCPK:MOTS

US$279.0k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 ViewRay
과거 주가
현재 주가	US$0.0001
52주 최고치	US$4.96
52주 최저치	US$0.000001
베타	0.76
11개월 변경	-98.88%
3개월 변경 사항	-99.57%
1년 변경 사항	-100.00%
33년 변화	-100.00%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	VRAY.Q	US Medical Equipment	US 마켓
7D	0%	-0.8%	0.7%
1Y	-100.0%	21.2%	32.3%

수익률 대 산업: VRAY.Q 지난 1년 동안 -0.5 %를 반환한 US Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: VRAY.Q 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is VRAY.Q's price volatile compared to industry and market?
VRAY.Q volatility
VRAY.Q Average Weekly Movement	2,748.1%
Medical Equipment Industry Average Movement	8.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: VRAY.Q 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: VRAY.Q 의 주간 변동성은 지난 1년 동안 1401% 에서 2748% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2004	295	Paul Ziegler	www.viewray.com

ViewRay, Inc. 기본 사항 요약

ViewRay 의 수익과 매출은 시가총액과 어떻게 비교하나요?
VRAY.Q 기본 통계
시가총액	US$18.34k
수익(TTM)	-US$110.41m
수익(TTM)	US$105.86m

0.0x

P/S 비율

0.0x

P/E 비율

VRAY.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
VRAY.Q 손익 계산서(TTM)
수익	US$105.86m
수익 비용	US$97.34m
총 이익	US$8.52m
기타 비용	US$118.94m
수익	-US$110.41m

최근 보고된 수익

Mar 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.60
총 마진	8.05%
순이익 마진	-104.30%
부채/자본 비율	140.7%

VRAY.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

VRAY.Q 주식 개요

보상

위험 분석

ViewRay, Inc. 경쟁사

OTCPK:NNMX

US$4.9k

OTCPK:ABMC

US$4.8k

OTCPK:LHDX.Q

US$4.2k

OTCPK:MOTS

US$279.0k

가격 내역 및 성능

최근 뉴스 및 업데이트

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company